Heart disease has been the leading cause in developed economies for the last half century. In 2017, 30% of deaths in the United States were related to heart disease1.
FUJIFILM Cellular Dynamics’s iPSC technology has revolutionized cardiac disease and cardiotoxicity research and pharmaceutical discovery, enabling in vitro modeling of arrhythmia, cardiomyopathies, Brudaga syndrome, and screening for cardiotoxicity liability.
Our flagship product, iCell® Cardiomyocytes, is the gold standard for in vitro cardiac research and has been in continuous production for research use for over 10 years.
We also offer a variety of iPSC-derived cardiac cells, including engineered disease models, healthy cells, cardiac progenitor cells and endothelial cells to help combat this growing epidemic of the 21st century.
